U.S. FDA issues four observations to Gland Pharma plant near Hyderabad
In short
The U.S. FDA found four observations at Gland Pharma’s formulation plant in Dundigal near Hyderabad. The inspection was unannounced and took place from October 12 to 23.
The findings could matter for the company’s manufacturing compliance. The report does not say how serious the observations are or whether Gland Pharma must take any action.
What the reporting says
The U.S. FDA issued four Form 483 observations to Gland Pharma’s formulation facility in Dundigal near Hyderabad after an unannounced inspection from October 12 to 23. The reported inspection focused on current good manufacturing practice compliance. The immediate consequence is a regulatory overhang for the plant, but the source does not state the severity of the observations or any next steps from Gland Pharma.
Why it matters
The U.S. FDA issued four Form 483 observations after an unannounced current good manufacturing practice inspection at Gland Pharma’s facility in Dundigal near Hyderabad, carried out between October 12 and 23. That creates a compliance issue for the company’s formulation operations. However, the reporting does not specify the nature of the observations, whether there were any product impacts, or what response Gland Pharma may have made.